EGFR and non-small cell lung carcinoma: The cobas (cobas EGFR Mutation Test ver 2; Roche Molecular Systems, Pleasanton, CA, USA) is the only ctDNA‐based EGFR mutation assay that is currently approved in Japan, as well as other countries/regions, for the detection of EGFR resistance mutations in patients with NSCLC.